Key Takeaways
- Tepid H1, H2 rebound promised: Revenue grew just 3% YoY in Q2 as large export clients pushed demand to H2, but management reaffirmed its full-year 20% growth guidance with similar margins.
- Working capital stretched, not broken: Debtor days rose on extended credit to strategic customers, but October collections are already unwinding the bulge and normalization is expected in two quarters.
- Balance sheet reset via promoter-led infusion: A ₹550 crores preferential issue, driven by the promoter increasing his stake, will retire ~80% of long-term debt and become EPS accretive.
- Fluorination is the mix-shift story: The fluorination stream hit ~15% of H1 revenue and is on track to reach ~20% by year-end, with a long-term target of 25–30% of an expanded base.
- What to watch next quarter: Whether the H2 demand catch-up materializes as customer forecasts imply, the pace of debtor unwinding, and any concrete FY25 capex number.
Demand & Revenue Drivers
- Export push-out, not loss: Large global customers requested demand be shifted to H2, so Q2 softness was telegraphed from Q1. Management expects H2 export numbers to normalize toward historical trends.
- Domestic strength carried H1: Domestic customers drove the 11% H1 revenue growth, with the domestic/export split now at 45/55. Management did not break out growth by segment.
- Portfolio insulation holds: Over 70–75% of the portfolio is patented, recently off-patented, or long-generic products tied to innovators, limiting exposure to multi-customer generic price wars.
- LOI crystallization is competence-led: New contracts and LOIs, expected to add ~₹1,000 crores over 3–4 years, are converting because of technical competence built over 5–7 years, supply-chain capability via Tanfac, on-ground teams in target geographies, and an execution track record.
- China impact is pass-through: For the CSM business with one-to-one innovator relationships and pass-through pricing, the China supply-chain disruption is "practically pass-through," leaving the company "reasonably insulated."
Anand Desai: "Our order book remains strong, despite the challenging environment giving us a good visibility of robust growth for the current financial year, and we are positive on maintaining our guidance of 20% growth with similar margins."
Working Capital & Balance Sheet
- Debtor bulge is temporary and strategic: Higher debtors reflect increased sales to large strategic global customers and domestic sales, both of which carry longer cycles. Management extended credit as temporary support and October collections are already unwinding the bulge.
- Inventory to normalize with revenue: Inventory will combine and rationalize as revenue picks up in H2.
- Preferential issue mechanics: The ₹550 crores issue is promoter-led: Anand Desai increasing his shareholding was the primary driver, with other investors joining alongside. Approximately 80% of proceeds will repay long-term debt, reducing interest cost and improving EPS. Promoter funds are expected by early December 2023; warrants bring 25% now and the balance within 18 months.
Vishal Thakkar: "I would put it this way that if you see Anand Desai is the founding promotor, he has been increasing his shareholding in the company. And that has been the primary driver for this press."
Fluorination & Portfolio Evolution
- Fluorination scaling toward 20%: The stream contributed ~15% of H1 revenue and is expected to reach ~20% by FY24 year-end, with a long-term target of 25–30% of an expanded revenue base.
- Molecule launch cadence intact: Three molecules launched in Q2, five in FY24 so far, taking total products to 58. Five more are in the pipeline for the next two quarters, with 10 new molecules targeted for the full year.
- Pharma CDMO entry via partnership: An MOU with TI Group and 3xper aims to develop newer pharma molecules, leveraging their market understanding and Anupam's chemistry and process strength. Mr. Govindaraj, ex-MD of Aurobindo Pharma, is guiding innovator interaction. No timeline was given for P&L impact.
Margins & Cost Structure
- Margin held at 28% despite pricing pressure: EBITDA margin stayed at 28% even as the generic agrochemical segment faced pricing headwinds. Price deflation impact was limited; robust volumes and raw material costs in the 40s range mean small percentage moves in realization.
- Official margin band is 26–28%: Management guides to 26–28% on a standalone basis and similar on consolidated, cautioning against extrapolating the 29% print. The stated endeavor is to improve every basis point.
- Capex peak passing: The balance ₹670 crores of the current cycle will be spent in the next 6–9 months. FY25 capex will be maintenance and debottlenecking only, not large capacity addition, though management declined to give a specific number yet.
Vishal Thakkar: "I would really tend to guide at 26% to 28%, though we have done 29%, but I would always caution that 26% to 28% is a fair guidance that I would want to give. If we perform better, we would definitely be happy and that's our endeavour as a management that we improve every single bps of my EBITDA margin."
Competitive Position & External Environment
- Structural tailwind from peer weakness: European peers are becoming less competitive and Chinese peers less preferable, creating an opening that Anupam fills with its experience, product portfolio, Tanfac supply chain, and value-tree approach.
- China destocking has a quarter or two to run: Management believes Chinese players will clear excess inventory in one to two quarters, after which new stock will enter the market priced to current levels.
- Six-month pricing agreements progressing: Approximately 60% are done, a couple remain pending, and the company is working on them.
Vishal Thakkar: "We believe that it's a quarter or two quarter that they would be done with that stock and the new stock will come into the market where they will have to also price the products as per the current market prices."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | 20% growth with similar margins | FY24 |
| Debtor normalization | Debtor days to return to normal levels | Next two quarters |
| Preferential issue proceeds | Promoter funds received | First/second week of December 2023 |
| Fluorination revenue mix | Reach ~20% of revenue | FY24 year-end |
| Fluorination revenue mix | Reach 25–30% of expanded revenue base | Long-term (no date) |
| Capex spend | Balance ₹670 crores deployed | Next 6–9 months |
| FY25 capex character | Maintenance and debottlenecking only, no large capacity addition | FY25 |
| Molecule launches | Five molecules in pipeline launched | Next two quarters |
| New LOI/contract revenue | ~₹1,000 crores added, staggered | Over 3–4 years |
| Carbon neutrality | Net carbon neutral on energy consumption | By 2027 |
| EBITDA margin | 26–28% on standalone, similar consolidated | Ongoing |
Key Metrics
| Metric | Q2 FY24 |
|---|---|
| Total revenue | ₹396 cr, up 3% YoY from ₹383 cr in Q2 FY23 |
| Total revenue (H1 FY24) | ₹794 cr, up 11% YoY from ₹718 cr in H1 FY23 |
| EBITDA (including other income) | ₹111 cr, up 10% YoY from ₹101 cr in Q2 FY23 |
| EBITDA margin | 28% |
| EBITDA (H1 FY24, including other income) | ₹225 cr, up 18% YoY from ₹190 cr in H1 FY23 |
| EBITDA margin (H1 FY24) | 28% |
| Profit after tax | ₹49 cr, up 2% YoY from ₹48 cr in Q2 FY23 |
| Profit after tax (H1 FY24) | ₹101 cr, up 12% YoY from ₹90 cr in H1 FY23 |
| Revenue growth guidance | 20% for FY24, with similar margins |
| EBITDA margin guidance | 26% to 28% on standalone basis, consolidated similar historically |
| LOIs and contracts signed | ₹7,669 cr as of September 30, 2023 |
| New molecules launched in FY24 | 5 (3 in Q2), total products now 58; 5 more planned in coming two quarters |
| Revenue from fluorination | ~15% of revenue in H1 FY24, expected ~20% by year-end, long-term target 25% to 30% |
| Domestic vs export revenue split | 45% domestic, 55% export |
| Top 10 customer concentration | 83% of total revenue, across 24 products |
| Cash equivalents | ₹404 cr as of September 30, 2023 |
| Preferential issue | ₹550 cr, primarily to retire long-term debt, EPS accretive |
| Capex announced | ₹670 cr total, ₹234 cr incurred to date, balance over next 6 to 9 months |
| Revenue potential from current capex | ₹1,700 to ₹1,800 cr from existing plants; total capex plus other investments implies ₹2,000 to ₹3,000 cr revenue |
| New contracts/LOIs expected addition | ~₹1,000 cr in revenue over 3 to 4 years |
| Contractual or contractual-behaviour revenue | ~70%-plus of total revenue |
| Six-month pricing agreements status | ~60% of contractor revenue covered, a couple pending |